Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine

噬菌体在肠道内去定植耐万古霉素肠球菌的机制基础

基本信息

批准号：
10810149
负责人：
Breck A Duerkop
金额：
$ 46.05万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-14 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10810149
关键词：
Active Sites Address Adherence Anti-Bacterial Agents Antibiotic Resistance Antibiotic susceptibility Antibiotics Antigens Automobile Driving Bacteria Bacterial Antibiotic Resistance Bacterial Infections Bacteriophages Biogenesis Biological Products Cell Wall Cell surface Combined Antibiotics Combined Modality Therapy Daptomycin Defect Development Drug Targeting Drug resistance Emergency Situation Enterococcus Enterococcus faecalis Enterococcus faecium Genes Gram-Positive Bacteria Health Hospitals Human Hydrolase Infection Intestines Knowledge Measures Mediating Mediator Mutation N-Acetylmuramoyl-L-alanine Amidase Nosocomial Infections Outcome Penicillin-Binding Proteins Peptidoglycan Phenotype Polysaccharides Population Precision therapeutics Predatory Behavior Public Health Resistance Resistance development Shapes Surface Therapeutic Traction Vancomycin Vancomycin resistant enterococcus Variant Virulence Virus Work bacterial fitness beta-Lactams clinically relevant cost fitness gut colonization immune clearance microbiota model organism mutant novel novel strategies novel therapeutic intervention novel therapeutics opportunistic pathogen pathogen pathogenic bacteria pressure resistant strain

项目摘要

PROJECT SUMMARY Bacteriophages (phages) are gaining traction as antibacterial therapeutics largely due to several high profile uses as emergency-approved experimental biologics. A perceived problem with phage therapy is that the development of bacterial phage resistance will curtail the use of phages as clinically relevant therapies. This conclusion overlooks a fundamental flaw in the development of phage resistance, that is, bacteria often incur reduced fitness as a result of acquired phage resistance. These fitness tradeoffs include enhanced antibiotic susceptibility, reduced virulence, and the inability to stably colonize their host. The work described in this proposal will capitalize on the emergence of phage resistance as a means to successfully treat recalcitrant opportunistic pathogens that reside in the intestine. We will use the Gram-positive intestinal commensals and opportunistic pathogens Enterococcus faecalis and Enterococcus faecium as model organisms to determine how phage resistance phenotypes influence their fitness in the intestine and whether these outcomes can be leveraged as novel therapeutic approaches. Specifically, we will define the mechanisms that drive phage resistance fitness defects of E. faecalis and E. faecium within the intestine by executing three specific aims: 1) to define the mechanism(s) driving the intestinal colonization deficiency of phage resistant strains harboring cell surface exopolysaccharide mutations; 2) to examine how phage-mediated mutations in the peptidoglycan hydrolase gene sagA result in antibiotic sensitivity; and 3) to determine if phage-antibiotic combinations reduce enterococcal intestinal colonization.

项目摘要噬菌体（噬菌体）作为抗菌疗法的吸引用作紧急批准的实验生物制剂。噬菌体疗法的一个感知问题是细菌噬菌体耐药性的发展将减少噬菌体作为临床相关疗法的使用。这结论忽略了噬菌体抗性发展中的基本缺陷，也就是说，细菌经常发生因获得的噬菌体抗性而降低了适应性。这些健身权衡包括增强的抗生素敏感性，毒力降低以及无法稳定地定居其宿主。其中描述的工作提案将利用噬菌体抵抗的出现，以此作为成功治疗顽强的一种手段位于肠道中的机会性病原体。我们将使用革兰氏阳性的肠口气和机会性病原体粪肠球菌和肠球菌作为模型生物噬菌体抗性表型如何影响其在肠道中的适应性以及这些结果是否可以杠杆作为新颖的治疗方法。具体而言，我们将定义驱动噬菌体的机制通过执行三个特定目的：1）定义驱动抗噬菌体菌株的肠道定植缺乏的机制表面外多糖突变； 2）检查噬菌体介导的突变如何在肽聚糖中水解酶基因传奇导致抗生素敏感性； 3）确定噬菌体抗生素组合是否减少肠球菌肠道定殖。